Search

Your search keyword '"I. Bieche"' showing total 216 results

Search Constraints

Start Over You searched for: Author "I. Bieche" Remove constraint Author: "I. Bieche"
216 results on '"I. Bieche"'

Search Results

1. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

2. Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants

3. 21TiP Molecular alterations predictive of outcome in early staged cervical cancer: A translational investigation in the international validation study of sentinel node biopsy in early cervical cancer SENTICOL III

4. 38MO Validation study of the ShallowHRDv2 assay for homologous recombination deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial

5. Tumor

6. Profil moléculaire des patients atteints de cancer bronchique compliqué de métastases cérébrales inclus dans l’essai de recherche clinique SAFIR-02 LUNG et évolution cérébrale sous traitement

7. Additional file 1 of Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

8. Additional file 2 of Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

10. Oligonucleotide microarray analysis of estrogen receptor α-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen

11. [Not Available]

12. 169 MicroRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature predictive of aggressiveness and prognosis of muscle-invasive bladder cancer

13. Delineation of molecular subgroups of breast cancer with distinct genomic profiles and different clinical courses: a novel definition of disease subclasses

14. TaqI RFLP of the TGF alpha gene in breast cancer

15. Non-invasive multi-cancer detection using DNA hypomethylation of LINE-1 retrotransposons.

16. Paving the path towards tissue-agnostic drug approval in oncology.

18. The genomic and transcriptomic landscape of metastastic urothelial cancer.

19. Viral whole genome sequencing reveals high variations in APOBEC3 editing between HPV risk categories.

20. Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.

21. p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.

22. Mosaic BRCA1 promoter methylation contribution in hereditary breast/ovarian cancer pedigrees.

23. Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement.

24. Germline HPF1 retrogene insertion in RB1 gene involved in cancer predisposition.

25. Thrombin receptor PAR1 silencing in endothelial colony-forming cells modifies stemness and vasculogenic properties.

26. MSH3 : a confirmed predisposing gene for adenomatous polyposis.

27. Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.

28. Donor/recipient origin of lung cancer after lung transplantation by DNA short tandem repeat analysis.

30. PRMT5 triggers glucocorticoid-induced cell migration in triple-negative breast cancer.

31. First report of medulloblastoma in a patient with MUTYH-associated polyposis.

32. Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.

33. APC germline pathogenic variants and epithelial ovarian cancer: causal or coincidental findings?

34. Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial.

35. Evolution of synchronous female bilateral breast cancers and response to treatment.

36. Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer.

37. Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort.

38. Microsatellite instability detection in breast cancer using drop-off droplet digital PCR.

39. The Identification of Large Rearrangements Involving Intron 2 of the CDH1 Gene in BRCA1/2 Negative and Breast Cancer Susceptibility.

40. Genomics to select treatment for patients with metastatic breast cancer.

42. Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial.

43. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.

44. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.

45. PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.

46. Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS.

47. Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma.

48. Differential Expression of Genes Involved in Metabolism and Immune Response in Diffuse and Intestinal Gastric Cancers, a Pilot Ptudy.

49. Value of the loss of heterozygosity to BRCA1 variant classification.

50. Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus-Associated Gastric Adenocarcinoma With ERBB2 Amplification.

Catalog

Books, media, physical & digital resources